Y
Yasushi Goto
Researcher at University of Tokyo
Publications - 186
Citations - 2763
Yasushi Goto is an academic researcher from University of Tokyo. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 20, co-authored 130 publications receiving 1587 citations.
Papers
More filters
Journal ArticleDOI
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kazuhiko Nakagawa,Edward B Garon,Takashi Seto,Makoto Nishio,Santiago Ponce Aix,Luis Paz-Ares,Chao-Hua Chiu,Keunchil Park,Silvia Novello,Ernest Nadal,Fumio Imamura,Kiyotaka Yoh,Jin-Yuan Shih,Kwok Hung Au,Denis Moro-Sibilot,Sotaro Enatsu,Annamaria Zimmermann,Bente Frimodt-Moller,Carla Visseren-Grul,Martin Reck,Quincy Chu,Alexis B. Cortot,Jean-Louis Pujol,Elizabeth Fabre,Corinne Lamour,Helge Bischoff,Jens Kollmeier,M Kimmich,Walburga Engel-Riedel,Stefan Hammerschmidt,Wolfgang Schütte,Konstantinos N. Syrigos,James Chung-Man Ho,Kwok-Hung Au,Andrea Ardizzoni,Giulia Pasello,Vanessa Gregorc,Alessandro Del Conte,Domenico Galetta,Toshiaki Takahashi,Toru Kumagai,Katsuyuki Hotta,Yasushi Goto,Yukio Hosomi,Hiroshi Sakai,Yuichi Takiguchi,Young Hak Kim,Takayasu Kurata,Hiroyuki Yamaguchi,Haruko Daga,Isamu Okamoto,Miyako Satouchi,Satoshi Ikeda,Kazuo Kasahara,Shinji Atagi,Koichi Azuma,Keisuke Aoe,Yoshitsugu Horio,Nobuyuki Yamamoto,Hiroshi Tanaka,Satoshi Watanabe,Naoyuki Nogami,Tomohiro Ozaki,Ryo Koyama,Tomonori Hirashima,Hiroyasu Kaneda,Keisuke Tomii,Yuka Fujita,Masahiro Seike,Naoki Nishimura,Terufumi Kato,Masao Ichiki,Hideo Saka,Katsuya Hirano,Yasuharu Nakahara,Shunichi Sugawara,Sang-We Kim,Young Joo Min,Hyun Woo Lee,Jin-Hyoung Kang,Ho Jung An,Ki Hyeong Lee,Jin Soo Kim,Gyeong-Won Lee,Sung Yong Lee,A. Alexandru,Anghel Adrian Udrea,Óscar Juan-Vidal,Ernest Nadal-Alforja,Ignacio Gil-Bazo,Santiago Ponce-Aix,Belén Rubio-Viqueira,Miriam Alonso Garcia,Enriqueta Felip Font,Jose Fuentes Pradera,Juan Coves Sarto,Meng-Chih Lin,Wu Chou Su,Te Chun Hsia,Gee-Chen Chang,Yu-Feng Wei,Jian Su,Irfan Cicin,Tuncay Göksel,Hakan Harputluoglu,Ozgur Ozyilkan,Ivo Henning,Sanjay Popat,Olivia Hatcher,Kathryn Mileham,Jared Acoba,Edward B. Garon,Gabriel Jung,Moses Sundar Raj,William J. Martin,Shaker R. Dakhil +115 more
TL;DR: The RELAY trial as mentioned in this paper evaluated erlotinib, an EGFR tyrosine kinase inhibitor (TKI) standard of care, plus ramucirumab, a human IgG1 VEGFR2 antagonist, or placebo in patients with untreated EGFR-mutated metastatic NSCLC.
Journal ArticleDOI
Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.
Bob T. Li,Egbert F. Smit,Yasushi Goto,Kazuhiko Nakagawa,Hibiki Udagawa,Julien Mazieres,Misako Nagasaka,Lyudmila Bazhenova,Andreas Saltos,Enriqueta Felip,Jose M. Pacheco,Maurice Pérol,Luis Paz-Ares,Kapil Saxena,Ryota Shiga,Yingkai Cheng,Suddhasatta Acharyya,Patrik Vitazka,Javad Shahidi,David Planchard,Pasi A. Jänne,DESTINY-Lung Trial Investigators +21 more
TL;DR: In this paper, trastuzumab deruxtecan (6.4 mg per kilogram of body weight) was administered to patients with metastatic HER2-mutant non-small-cell lung cancer (NSCLC) that was refractory to standard treatment.
Journal ArticleDOI
Japanese translation and linguistic validation of the US National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Tempei Miyaji,Yukiko Iioka,Yukiko Iioka,Yujiro Kuroda,Daigo Yamamoto,Satoru Iwase,Yasushi Goto,Masahiro Tsuboi,Hiroki Odagiri,Yu Tsubota,Takashi Kawaguchi,Naoko Sakata,Ethan Basch,Takuhiro Yamaguchi,Takuhiro Yamaguchi +14 more
TL;DR: The study provides preliminary evidence supporting the linguistic validity of the Japanese version of PRO-CTCAE, and further cognitive interviewing is warranted for PRO- CTCAE items relating to sexuality and anxiety and for response options on severity attribute items.
Journal ArticleDOI
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.
Egbert F. Smit,Kazuhiko Nakagawa,Misako Nagasaka,Enriqueta Felip,Yasushi Goto,Bob T. Li,Jose M. Pacheco,Haruyasu Murakami,Fabrice Barlesi,Andreas Saltos,Maurice Pérol,Hibiki Udagawa,Kapil Saxena,Ryota Shiga,F. Guevara,Suddhasatta Acharyya,Javad Shahidi,David Planchard,Pasi A. Jänne +18 more
TL;DR: T-DXd is an antibody-drug conjugate composed of an anti-HER2 antibody, cleavable tetrapeptide-based linker, and topoisomerase I inhibitor payload that has shown promise in a phase I trial.
Journal ArticleDOI
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
Hiroaki Akamatsu,Kiichiro Ninomiya,Hirotsugu Kenmotsu,Masahiro Morise,Haruko Daga,Yasushi Goto,Toshiyuki Kozuki,Satoru Miura,Takaaki Sasaki,Akihiro Tamiya,Shunsuke Teraoka,Yukari Tsubata,Hiroshige Yoshioka,Yoshihiro Hattori,Chiyo K. Imamura,Yuki Katsuya,Reiko Matsui,Yuji Minegishi,Hidenori Mizugaki,Kaname Nosaki,Yusuke Okuma,Setsuko Sakamoto,Takashi Sone,Kentaro Tanaka,Shigeki Umemura,Takeharu Yamanaka,Shinsuke Amano,Kazuo Hasegawa,Satoshi Morita,Kazuko Nakajima,Makoto Maemondo,Takashi Seto,Nobuyuki Yamamoto +32 more
TL;DR: An English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC, stages IV is reported, proposing to categorize patients into three entities: (1) driver oncogene-positive, (2) PD-L1 ≥ 50%, and (3) others.